Pharmion and MethylGene Collaborate On Sirtuin Inhibitors To Treat Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
MethylGene could get up to $79 million in milestones, 21 percent in U.S. royalties.
You may also be interested in...
MethylGene Oncology Agent Shows Activity In NHL Clinical Trial
MGCD0103 shows 15 percent response rate in subset of NHL patients, tumor shrinkage, firm reports at ASCO.
MethylGene Oncology Agent Shows Activity In NHL Clinical Trial
MGCD0103 shows 15 percent response rate in subset of NHL patients, tumor shrinkage, firm reports at ASCO.
GSK To Pay $720 Million For Sirtris
Independent unit will target diabetes and diseases of aging, deal crafter tells “The Pink Sheet” DAILY.